# FDA approves a new medicine from Denali Therapeutics for a condition called Hunter syndrome.

*biotech · news · 2026-03-26 · KFF Health News*

## Key points

- The FDA approved Denali Therapeutics' enzyme replacement therapy for Hunter syndrome, not a gene therapy.
- Denali's drug can enter the brain and slow cognitive decline in two-thirds of Hunter syndrome patients.
- Merck is acquiring Terns Pharmaceuticals and its experimental leukemia drug in a nearly $6 billion cash deal.
- Non-physician clinicians now write 40% of antipsychotic prescriptions for older adults in Medicare.

**Companies:** Merck, Denali Therapeutics, Terns Pharmaceuticals

[Read the full story on KFF Health News](https://kffhealthnews.org/morning-breakout/fda-approves-hunter-syndrome-drug-on-heels-of-similar-drug-rejections/)

---

Canonical: https://newsio.io/n/ef19cc7e-7656-48d1-8359-d593c0e97198/fda-approves-a-new-medicine-from-denali-therapeutics-for-a-condition-called-hunt
Summarized by Newsio from KFF Health News. https://newsio.io/how-it-works